Image of common hill myna bird (Gracula religiosa intermedia) on nature background. Bird. Animals. Image via Depositphotos. Creating a bird-friendly backyard is not only a delightful hobby but also a ...

Image via Pixabay The act of following you provides a bonding opportunity ... A woman lovingly holds her happy Sheltie dog in a sunny outdoor setting, enjoying a moment of joy. Photo by Blue Bird via ...

Flying high as one of the world’s premier developers of gene therapies in early 2018, bluebird bio’s share price hit a dizzying $2,300 apiece. But seven years later—after failing to build a ...

bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions ...

Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a publicly traded company. The agreement comes after years of financial ...

Bluebird bio to be acquired by Carlyle Group & SK Capital, offering up to $9.84/share based on product performance. Former Mirati CEO David Meek set to lead bluebird post-acquisition, with deal ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million. Bluebird on ...

For a full version of this story, visit STAT. Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $ ...

JPMorgan upgraded Bluebird Bio (BLUE) to Neutral from Underweight without a price target after the company entered into a definitive agreement to be taken private. The firm expects a completed ...

bluebird has opted to launch it at a cost of $2.8 million, which compares to the $1.7 million price tag attached to the therapy when it was first made available in Europe, and is also well above ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million. Bluebird makes three gene therapies: Zynteglo for beta thalassemia, Lyfgenia for sickle cell ...

Bird flu is here to stay. The H5N1 avian influenza is proliferating among U.S. cows and there are now two strains circulating among mammals and birds. Though there are only 68 confirmed cases in ...